Description

ANGISPAN TR 2.5 MG (1X25)

Indications

ANGISPAN TR 2.5 MG is primarily indicated for the management of chronic stable angina pectoris. It is utilized as a therapeutic option to alleviate symptoms associated with angina, a condition characterized by chest pain due to inadequate blood supply to the heart muscle. Additionally, it may be used in certain cases of hypertension as part of a comprehensive treatment plan. The medication is designed to improve exercise tolerance and overall quality of life for patients suffering from these cardiovascular conditions.

Mechanism of Action

The active ingredient in ANGISPAN TR 2.5 MG is isosorbide mononitrate, a nitrate that acts as a vasodilator. Upon administration, isosorbide mononitrate is converted to nitric oxide, which relaxes the smooth muscles of blood vessels. This vasodilation leads to a reduction in myocardial oxygen demand by decreasing preload and afterload on the heart. As a result, the heart requires less oxygen, alleviating the symptoms of angina. The sustained-release formulation of ANGISPAN TR ensures a prolonged therapeutic effect, allowing for once-daily dosing.

Pharmacological Properties

ANGISPAN TR 2.5 MG exhibits several pharmacological properties that contribute to its efficacy in treating angina and hypertension. The onset of action typically occurs within 30 to 60 minutes post-administration, with peak plasma concentrations reached within 2 to 4 hours. The duration of action can extend up to 24 hours, making it suitable for once-daily dosing. The pharmacokinetics of isosorbide mononitrate demonstrate a high bioavailability of approximately 100%, with minimal first-pass metabolism. The drug is primarily excreted as metabolites in the urine, indicating a favorable elimination profile.

Contraindications

ANGISPAN TR 2.5 MG is contraindicated in patients with a known hypersensitivity to isosorbide mononitrate or any of its excipients. It should not be used in individuals with severe anemia, closed-angle glaucoma, or during acute myocardial infarction. Additionally, the medication is contraindicated in patients who are concurrently using phosphodiesterase inhibitors, such as sildenafil, due to the risk of severe hypotension. Caution is advised in patients with hypotension or those who have experienced syncope.

Side Effects

Common side effects associated with ANGISPAN TR 2.5 MG include headache, dizziness, and flushing. These effects are primarily due to the vasodilatory action of the drug. Other potential side effects may include hypotension, palpitations, and gastrointestinal disturbances such as nausea. Rare but serious adverse effects can include severe allergic reactions, including anaphylaxis, and methemoglobinemia. Patients should be advised to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of ANGISPAN TR 2.5 MG is one tablet taken orally once daily, preferably in the morning. It is important to swallow the tablet whole with a glass of water, without chewing or crushing it, to maintain the integrity of the sustained-release formulation. Dosage adjustments may be necessary based on individual patient response and tolerability. Healthcare providers should regularly monitor patients for efficacy and side effects, especially during the initiation of therapy or after any dosage adjustments.

Interactions

ANGISPAN TR 2.5 MG may interact with various medications, potentially altering its effectiveness or increasing the risk of adverse effects. Notably, concurrent use with phosphodiesterase inhibitors can lead to significant hypotension. Other interactions may occur with antihypertensive agents, leading to additive effects on blood pressure. Caution should be exercised when combining ANGISPAN TR with other vasodilators or alcohol, as these can enhance the hypotensive effects. It is essential for patients to inform their healthcare providers about all medications and supplements they are taking to avoid potential interactions.

Precautions

Before initiating treatment with ANGISPAN TR 2.5 MG, healthcare providers should conduct a thorough assessment of the patient’s medical history and current medications. Special precautions should be taken in patients with renal or hepatic impairment, as these conditions may affect drug metabolism and clearance. Additionally, patients with a history of hypotension or those who are dehydrated should be monitored closely. It is also advisable to avoid abrupt discontinuation of the medication, as this may precipitate angina or myocardial infarction. Patients should be educated about the signs and symptoms of hypotension and advised to rise slowly from sitting or lying positions to minimize the risk of dizziness or fainting.

Clinical Studies

Clinical studies have demonstrated the efficacy of ANGISPAN TR 2.5 MG in reducing the frequency and severity of angina attacks. In a randomized, double-blind trial, patients receiving isosorbide mononitrate reported a significant improvement in exercise tolerance and a reduction in anginal episodes compared to placebo. Furthermore, long-term studies have indicated that sustained-release formulations provide consistent therapeutic effects with a favorable safety profile. These findings support the use of ANGISPAN TR as a reliable option for patients with chronic stable angina and hypertension.

Conclusion

ANGISPAN TR 2.5 MG is an effective medication for the management of chronic stable angina and hypertension. With its unique mechanism of action as a vasodilator, it provides relief from anginal symptoms and improves quality of life for patients. Understanding the pharmacological properties, potential side effects, and necessary precautions is essential for optimizing treatment outcomes. As with any medication, responsible use and adherence to prescribed guidelines are critical for ensuring patient safety and therapeutic efficacy.